Cargando…
Editorial: FGF21 as a therapeutic target for obesity and insulin resistance: from rodent models to humans
Autores principales: | De Sousa-Coelho, A. L., Rodriguez-Rodriguez, R., Softic, S., Jonker, J. W., Relat, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441540/ https://www.ncbi.nlm.nih.gov/pubmed/37608789 http://dx.doi.org/10.3389/fendo.2023.1253675 |
Ejemplares similares
-
Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho
por: Aaldijk, Alexandra S., et al.
Publicado: (2023) -
FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
por: Tillman, Erik J., et al.
Publicado: (2020) -
FGF21 and Cardiac Physiopathology
por: Planavila, Anna, et al.
Publicado: (2015) -
FGF19 and FGF21 for the Treatment of NASH—Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human
por: Henriksson, Emma, et al.
Publicado: (2020) -
Obesity-resistance of UCP1-deficient mice associates with sustained FGF21 sensitivity in inguinal adipose tissue
por: Klein Hazebroek, Marlou, et al.
Publicado: (2022)